DIVI S LABORATORIES LTD vs JAGSONPAL PHARMACEUTICALS
A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs JAGSNPHARM on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability31
- Growth11
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
JAGSNPHARM takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
DIVISLAB takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 50.3%", "Promoter holding has increased by 1.17% over last quarter.", "Company's working capital requirements have reduced from 24.0 days to 11.0 days"]
- − ["The company has delivered a poor sales growth of 8.85% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.